Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rosuvastatin + aspirin + clopidogrel
- Development stage
- Unknown
- Lead developer
- Matias Healthcare
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Romatias Gold is a fixed-dose combination (FDC) medication containing rosuvastatin, aspirin, and clopidogrel. Developed by Matias Healthcare, it is indicated for the secondary prevention of cardiovascular events in patients with established atherosclerotic disease. Rosuvastatin is a statin that inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL-C levels. Aspirin acts as an antiplatelet agent by irreversibly inhibiting cyclooxygenase-1 (COX-1), which prevents the formation of thromboxane A2. Clopidogrel, a thienopyridine, further inhibits platelet aggregation by irreversibly antagonizing the P2Y12 receptor. Together, these three components provide comprehensive management of lipid levels and thrombotic risk.
- Brand names
- Romatias Gold
- Other names
- Rosuvastatin, Aspirin, ClopidogrelRosuvastatin plus Aspirin plus Clopidogrel
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)P2Y12 (Purinergic P2Y12 receptor)PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on rosuvastatin + aspirin + clopidogrel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rosuvastatin + aspirin + clopidogrel.